How Elafibranor treatment works

Elafibranor (Elafibranor) is a new oral small molecule drug that mainly acts as a peroxisome proliferator-activated receptor (PPAR) α/Delta dual agonists are used to treat metabolic diseases, especially non-alcoholic steatohepatitis (NASH) and other metabolic syndrome-related diseases. Ilafibratenol exerts synergistic effects on multiple pathological pathways by regulating lipid metabolism, anti-inflammatory and anti-fibrotic effects, providing innovative ideas for the treatment of complex diseases. This article will analyze the therapeutic mechanism of irafibratenol in detail and explore its potential clinical value.

1. PPARReceptors and their physiological functions

Peroxisome proliferator-activated receptor (PPAR) is a type of nuclear receptor transcription factor, which mainly includes three subtypes: PPARα, PPARγ and PPARδ. They play important regulatory roles in lipid metabolism, glucose homeostasis, inflammatory response and fibrosis. PPARα is mainly found in liver, heart and other tissues, regulating β-oxidation of fatty acids; PPARδ is widely expressed in skeletal muscle, liver and other tissues, promoting fatty acid oxidation and energy metabolism. By activating these two receptors, irafibratenol can regulate the body's metabolic balance and improve abnormal fat metabolism.

2. Mechanism of action of irafibratenol

Ilafibratenol, as a dual agonist ofPPARα/δ, can activate these two receptors at the same time, thereby producing therapeutic effects in many aspects. Specific mechanisms include:

Improve lipid metabolism: After elafibratenol activates PPARα and PPARδ, it promotes β- oxidation of fatty acids in the liver and surrounding tissues, reduces liver fat accumulation, and effectively reduces the occurrence of fatty liver. At the same time, irafibatenol can regulate blood lipid levels, reduce triglycerides and low-density lipoprotein cholesterol (LDL-C), and increase high-density lipoprotein cholesterol (HDL-C), which has obvious benefits for patients with metabolic syndrome.

Anti-inflammatory effect: The pathological basis of metabolic liver diseases such as NASH involves chronic low-grade inflammation. Ilafibratenol inhibits the expression of pro-inflammatory factors such as TNF-α and IL-6 by activating PPAR receptors, reducing inflammatory cell infiltration, alleviating liver inflammatory response, and protecting liver cells from inflammatory damage.

Anti-fibrosis effect: Liver fibrosis is a key link in the progression of NASH. Excessive collagen deposition leads to damage to liver function. Ilafibratenol can regulate the activity of hepatic stellate cells, inhibit collagen synthesis, reduce the degree of liver fibrosis, and delay the progression of the disease.

Improve insulin resistance: Ilafibratenol indirectly improves insulin sensitivity by regulating lipid metabolism and inflammatory status, contributing to the comprehensive management of patients with abnormal glucose and lipid metabolism.

3. Therapeutic effects in clinical studies

Ilafibratenol has shown good efficacy and safety in multiple clinical trials. In NASH patients, elafibratenol significantly improved liver fat content, inflammation markers, and fibrosis scores. Some patients achieved improvement in liver histology after treatment, accompanied by optimization of metabolic indicators. In addition, elafibratenol is well tolerated and has mild adverse reactions, making it suitable for long-term use.

Ilafibratenol exerts multi-dimensional therapeutic effects by activating PPARα and PPARδ dual receptors, including improving lipid metabolism, reducing inflammation and inhibiting fibrosis. This multi-target, coordinated regulation mechanism gives it unique advantages in the treatment of complex diseases such as non-alcoholic steatohepatitis and metabolic syndrome. In the future, with the accumulation of more clinical data, irafibratenol is expected to become an important part of the treatment of related metabolic diseases, bringing more effective treatment options and improving quality of life to patients.

Reference materials:https://www.drugs.com